Research & Development

Apexigen raises $73m to advance immuno-oncology product development

Apexigen, a clinical-stage biopharmaceutical company engaged in the discovery and development of a new generation of antibody therapeutics for oncology, has raised $73m in Series B And Series C financings.

Teneobio, Poseida extend collaboration to develop UniDabs for advanced CAR-T therapies

Teneobio and Poseida Therapeutics have entered into a new research collaboration and licensing agreement to develop novel CAR-T therapies using Teneobio’s heavy chain only domain antibodies (UniDabs).

Acadia, Neuren sign North American license deal for Rett syndrome treatment

Acadia Pharmaceuticals and Neuren Pharmaceuticals have signed an exclusive North American license agreement for the development and commercialization of trofinetide for Rett syndrome and other indications.

Biotechnology firm BioTime to secure $43m from Juvenescence

BioTime, a clinical-stage biotechnology company focused on degenerative diseases, has announced a new strategic alignment between AgeX Therapeutics and Juvenescence, for which the company will receive $21.6M in cash and $21.6M in a 7% convertible/redeemable note for 14.4M shares of AgeX Therapeutics.

Daiichi Sankyo signs licensing deal with Glycotope for Gatipotuzumab ADC

Japanese pharmaceutical company Daiichi Sankyo and clinical-stage immuno-oncology firm Glycotope have entered into an exclusive worldwide licensing agreement to develop an antibody drug conjugate (ADC).

Lilly extends cancer research collaboration with Dana-Farber

Eli Lilly and Company has extended its cancer research collaboration with Dana-Farber Cancer Institute for three more years.

Kite, Gadeta collaborate to advance gamma delta T cell receptor technology for solid tumors

Kite and Gadeta have entered into a strategic collaboration to develop novel gamma delta TCR therapies in various cancers.

Cambrex to buy Halo Pharma for $425m

Cambrex has agreed to acquire contract development and manufacturing organization (CDMO) Halo Pharma for about $425m.

Novartis to pay EUR95m to Galapagos and MorphoSys for skin drug rights

Novartis has agreed to make an upfront payment of EUR95m to Galapagos and MorphoSys to in-license IL-17C compound for atopic dermatitis.